Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Page 1
Liposuction for Advanced Lymphedema in a Multidisciplinary Team Setting in Australia: 5-Year Follow-Up.
Karlsson T, Mackie H, Koelmeyer L, Heydon-White A, Ricketts R, Toyer K, Boyages J, Brorson H, Lam T. Karlsson T, et al. Among authors: boyages j. Plast Reconstr Surg. 2024 Feb 1;153(2):482-491. doi: 10.1097/PRS.0000000000010612. Epub 2023 Apr 28. Plast Reconstr Surg. 2024. PMID: 37114928 Free PMC article.
For patients with leg lymphedema, the median preoperative volume difference was 3447 mL, which was reduced to 263 mL 1 year after surgery but increased to 669 mL 5 years after surgery. CONCLUSION: Suction-assisted lipectomy is a long-term option for the management of selec …
For patients with leg lymphedema, the median preoperative volume difference was 3447 mL, which was reduced to 263 mL 1 year after surgery bu …
The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting.
Choi JDW, Hughes TMD, Marx G, Boyages J, Rutovitz J, Hasovits C, Parasyn A, Edirimanne S, Ngui NK. Choi JDW, et al. Among authors: boyages j. Breast J. 2022 Jan 31;2022:1199245. doi: 10.1155/2022/1199245. eCollection 2022. Breast J. 2022. PMID: 35711899 Free PMC article.
CONCLUSION: This is the first Australian study reporting the experience with medium-term recurrence outcomes of using the Oncotype DX assay in breast cancer. ...
CONCLUSION: This is the first Australian study reporting the experience with medium-term recurrence outcomes of using the Oncotype DX …
L-Dex, arm volume, and symptom trajectories 24 months after breast cancer surgery.
Ridner SH, Shah C, Boyages J, Koelmeyer L, Ajkay N, DeSnyder SM, McLaughlin SA, Dietrich MS. Ridner SH, et al. Among authors: boyages j. Cancer Med. 2020 Jul;9(14):5164-5173. doi: 10.1002/cam4.3188. Epub 2020 Jun 1. Cancer Med. 2020. PMID: 32483861 Free PMC article. Clinical Trial.
The self-report sets demonstrated contingency coefficients of 0.20 (LSIDS-A soft tissue, P = .031) and 0.19 (FACTB+4, P = .044) with the L-Dex unit change trajectories. CONCLUSIONS: These data support the need for long-term (24 months) prospective surveillance with frequen …
The self-report sets demonstrated contingency coefficients of 0.20 (LSIDS-A soft tissue, P = .031) and 0.19 (FACTB+4, P = .044) with the L-D …
Vascularized Lymph Node Transfer for Patients with Breast Cancer-Related Lymphedema Can Potentially Reduce the Burden of Ongoing Conservative Management.
Ngo QD, Munot S, Mackie H, Czerniec S, Koelmeyer LA, Lam T, Heydon-White A, Suami H, Boyages J. Ngo QD, et al. Among authors: boyages j. Lymphat Res Biol. 2020 Aug;18(4):357-364. doi: 10.1089/lrb.2019.0048. Epub 2020 Jan 16. Lymphat Res Biol. 2020. PMID: 31944882
Conclusion: Our results warrant continuation of VLNT as a surgical treatment option for patients with BCRL and show that the burden of conservative management such as wearing garments can be reduced over time for some patients. Longer term follow-up with standardized measu …
Conclusion: Our results warrant continuation of VLNT as a surgical treatment option for patients with BCRL and show that the burden of conse …
Evolution of radiotherapy techniques in breast conservation treatment.
Boyages J, Baker L. Boyages J, et al. Gland Surg. 2018 Dec;7(6):576-595. doi: 10.21037/gs.2018.11.10. Gland Surg. 2018. PMID: 30687630 Free PMC article. Review.
Short courses of RT over 3-4 weeks are generally as effective as longer courses. Short-term follow-up of trials of APBI show promise for selected good prognosis subgroups. ...
Short courses of RT over 3-4 weeks are generally as effective as longer courses. Short-term follow-up of trials of APBI show promise …
Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis.
Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Stuart KE, et al. Among authors: boyages j. BMC Cancer. 2015 Nov 10;15:890. doi: 10.1186/s12885-015-1904-7. BMC Cancer. 2015. PMID: 26555555 Free PMC article.
BACKGROUND: To summarize data on long-term ipsilateral local recurrence (LR) and breast cancer death rate (BCDR) for patients with ductal carcinoma in situ (DCIS) who received different treatments. ...CONCLUSIONS: More local intervention was associated with greater local c …
BACKGROUND: To summarize data on long-term ipsilateral local recurrence (LR) and breast cancer death rate (BCDR) for patients with du …
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators. Cuzick J, et al. Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11. Lancet Oncol. 2015. PMID: 25497694 Free PMC article. Clinical Trial.
BACKGROUND: Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the IBIS-I trial, in …
BACKGROUND: Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy w …
Hormone replacement therapy and breast cancer risk in California.
Coombs NJ, Taylor R, Wilcken N, Fiorica J, Boyages J. Coombs NJ, et al. Among authors: boyages j. Breast J. 2005 Nov-Dec;11(6):410-5. doi: 10.1111/j.1075-122X.2005.00132.x. Breast J. 2005. PMID: 16297085
This figure increases to 3401 (17.4%) when the MWS RRs are applied. Use of estrogen-only HRT or short-term (approximately 5 years) use of combined HRT has a minimal effect on the cumulative risk calculated to the age of 79 years; application of the MWS data to a California …
This figure increases to 3401 (17.4%) when the MWS RRs are applied. Use of estrogen-only HRT or short-term (approximately 5 years) us …
16 results